Epidemiology and burden of Severe Acute Respiratory Infections (SARI) in the aftermath of COVID-19 pandemic: A prospective sentinel surveillance study in a Tunisian Medical ICU, 2022/2023.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Influenza, Human* ; COVID-19*/epidemiology ; COVID-19*/complications ; Respiratory Tract Infections* ; Pneumonia*/epidemiology; Humans ; Infant ; Sentinel Surveillance ; Prospective Studies ; Pandemics ; Intensive Care Units

Background: Severe Acute Respiratory Infections (SARI) caused by influenza and other respiratory viruses pose significant global health challenges, and the COVID-19 pandemic has further strained healthcare systems. As the focus shifts from the pandemic to other respiratory infections, assessing the epidemiology and burden of SARI is crucial for healthcare planning and resource allocation. Aim: to understand the impact of the post-pandemic period on the epidemiology of SARI cases, clinical outcomes, and healthcare resource utilization in Tunisia.
Methods: This is a prospective study conducted in a Tunisian MICU part of a national sentinel surveillance system, focusing on enhanced SARI surveillance. SARI cases from week 39/2022, 26 September to week 19/2023, 13 May were included, according to a standardized case definition. Samples were collected for virological RT-PCR testing, and an electronic system ensured standardized and accurate data collection. Descriptive statistics were performed to assess epidemiology, trends, and outcomes of SARI cases, and univariate/multivariate analyses to assess factors associated with mortality.
Results: Among 312 MICU patients, 164 SARI cases were identified during the study period. 64(39%) RT-PCR were returned positive for at least one pathogen, with influenza A and B strains accounting for 20.7% of cases at the early stages of the influenza season. The MICU experienced a significant peak in admissions during weeks 1-11/2023, leading to resource mobilization and the creation of a surge unit. SARI cases utilized 1664/3120 of the MICU-stay days and required 1157 mechanical ventilation days. The overall mortality rate among SARI cases was 22.6%. Age, non-COPD, and ARDS were identified as independent predictors of mortality.
Conclusions: The present study identified a relatively high rate of SARI cases, with 39% positivity for at least one respiratory virus, with influenza A and B strains occurring predominantly during the early stages of the influenza season. The findings shed light on the considerable resource utilization and mortality associated with these infections, underscoring the urgency for proactive management and efficient resource allocation strategies.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2023 Boussarsar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

PLoS One. 2021 Mar 22;16(3):e0248750. (PMID: 33750952)
BMC Public Health. 2019 Jun 6;19(1):694. (PMID: 31170955)
N Engl J Med. 2020 Feb 20;382(8):727-733. (PMID: 31978945)
Vaccines (Basel). 2023 Mar 31;11(4):. (PMID: 37112687)
Lancet Reg Health Am. 2021 Sep;1:100015. (PMID: 34386788)
Emerg Infect Dis. 2020 Aug;26(8):1933-1935. (PMID: 32339092)
J Med Internet Res. 2020 Aug 20;22(8):e21257. (PMID: 32750008)
East Mediterr Health J. 2016 Oct 02;22(7):460-467. (PMID: 27714740)
J Midwifery Womens Health. 2021 Jan;66(1):45-53. (PMID: 33522695)
Trans R Soc Trop Med Hyg. 2023 Mar 1;117(3):161-173. (PMID: 35929810)
J Infect Public Health. 2023 May;16(5):727-735. (PMID: 36947950)
Nat Rev Microbiol. 2018 Jan;16(1):60. (PMID: 29109554)
PLoS One. 2013 Dec 31;8(12):e83854. (PMID: 24391837)
Int J Infect Dis. 2022 Aug;121:184-189. (PMID: 35584744)
Am J Clin Oncol. 1982 Dec;5(6):649-55. (PMID: 7165009)
Influenza Other Respir Viruses. 2023 May 11;17(5):e13140. (PMID: 37180840)
Int J Environ Res Public Health. 2022 Aug 21;19(16):. (PMID: 36012053)
Vaccine. 2021 Jun 23;39(28):3645-3648. (PMID: 34078554)
Sci Rep. 2022 Jun 10;12(1):9616. (PMID: 35688869)
Vaccines (Basel). 2022 Apr 13;10(4):. (PMID: 35455354)
Nat Rev Dis Primers. 2018 Jun 28;4(1):3. (PMID: 29955068)
PLoS One. 2022 Jul 6;17(7):e0270814. (PMID: 35793318)
Influenza Other Respir Viruses. 2023 Apr 23;17(4):e13134. (PMID: 37102059)
PLoS One. 2021 Feb 24;16(2):e0247200. (PMID: 33626106)
Crit Care Explor. 2022 Oct 20;4(10):e0773. (PMID: 36284548)
Int J Infect Dis. 2023 Sep;134:39-44. (PMID: 37201863)
Front Med (Lausanne). 2022 Oct 10;9:977614. (PMID: 36300181)
Influenza Other Respir Viruses. 2023 Apr 26;17(4):e13133. (PMID: 37123813)
Euro Surveill. 2023 Jun;28(23):. (PMID: 37289427)
JAMA. 2012 Jun 20;307(23):2526-33. (PMID: 22797452)
Euro Surveill. 2021 Mar;26(11):. (PMID: 33739256)
Can Commun Dis Rep. 2021 Mar 31;47(3):142-148. (PMID: 34012338)
PLoS Med. 2007 Oct 16;4(10):e297. (PMID: 17941715)
Proc Natl Acad Sci U S A. 2019 Dec 26;116(52):27142-27150. (PMID: 31843887)
Emerg (Tehran). 2016 Winter;4(1):48-51. (PMID: 26862553)
Influenza Other Respir Viruses. 2020 Sep;14(5):575-586. (PMID: 32530142)

U51 IP000822 United States IP NCIRD CDC HHS

Date Created: 20231215 Date Completed: 20231218 Latest Revision: 20240131

20240131

PMC10723666

10.1371/journal.pone.0294960

38100529